CareDx Maintains Analyst Confidence Despite Quarterly Losses

Despite posting disappointing quarterly results and facing continued share price pressure, market analysts are demonstrating notable optimism toward CareDx. The transplantation diagnostics specialist is contending with declining profitability and regulatory headwinds, yet experts on Wall Street continue to identify significant potential in the equity.

CareDx?s second-quarter 2025 performance presented a complex financial snapshot. Revenue climbed 14% to $90.5 million; however, the company reported a GAAP net loss of $8.6 million, a significant swing into negative territory. A particularly sore point was the loss per share of $0.16, which sharply missed consensus estimates that had projected a profit of $0.12 per share.

Amid these challenges, several positive indicators emerged. The company?s adjusted EBITDA showed a marked improvement, reaching $9.1 million compared to a loss... Read more...